Top ▲
Target has curated data in GtoImmuPdb
Target id: 3067
Nomenclature: KIR3DL2 (CD158K)
Family: CD molecules
Annotation status:
Awaiting annotation
» Email us
Gene and Protein Information ![]() |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 1 | 455 | 19q13.42 | KIR3DL2 | killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 2 | |
| Mouse | 1 | 409 | Chromosome X, 58.77 cM | Kir3dl1 | killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 | |
| Gene and Protein Information Comments | ||||||
| Alternatively spliced transcript variants that encode different protein isoforms have been identified for human KIR3DL2 [1] and its mouse ortholog Kir3dl1. | ||||||
Previous and Unofficial Names ![]() |
| killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 | killer cell immunoglobulin-like receptor | cl-5 | Kirl1 (Mm) | nkat4 | nkat4a |
Database Links ![]() |
|
| Alphafold | P43630 (Hs) |
| ChEMBL Target | CHEMBL4630895 (Hs) |
| Ensembl Gene | ENSG00000240403 (Hs), ENSMUSG00000031424 (Mm) |
| Entrez Gene | 3812 (Hs), 245616 (Mm) |
| Human Protein Atlas | ENSG00000240403 (Hs) |
| KEGG Gene | hsa:3812 (Hs), mmu:245616 (Mm) |
| OMIM | 604947 (Hs) |
| Pharos | P43630 (Hs) |
| RefSeq Nucleotide | NM_006737 (Hs), NM_177749 (Mm) |
| RefSeq Protein | NP_006728 (Hs), NP_808417 (Mm) |
| UniProtKB | P43630 (Hs) |
| Wikipedia | KIR3DL2 (Hs) |
Download all structure-activity data for this target as a CSV file
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| KIR3DL2 mediates NK cell coinhibitory signals when it binds to MHC class I molecules on other cells. Binding to HLA-A3 , HLA-A11 [3] and HLA-B27 [4] has been reported, as has binding to CpG oligodeoxynucleotides [7]. KIR3DL2 is highly expressed on the malignant cells in cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome, and has been reported to promote resistance to NK cell-induced cell death in some CTCLs [8]. Blockade of the suppressive signal mediated by KIR3DL2 using a monoclonal antibody (Innate Pharma's IPH4102) is being investigated as a therapeutic approach for the treatment of T cell lymphomas such as Sézary syndrome [5-6,9]. |
| Immuno Process Associations | |||||||||
|
|||||||||
|
| General Comments |
| KIR3DL2 is one of a family of 18 human genes that encode MHC class I receptors on the surface of nautral killer (NK) cells and some cytotoxic T cell subsets (HGNC gene group link: Killer cell immunoglobulin like receptors (KIR)). Most KIR proteins mediate inhibitory signals that suppress the cytotoxic activity of the NK cell on which they are expressed. KIR3DL2 is an immuno-oncology therapeutic target. |
1. Döhring C, Samaridis J, Colonna M. (1996) Alternatively spliced forms of human killer inhibitory receptors. Immunogenetics, 44 (3): 227-30. [PMID:8662091]
2. Gauthier L, Schneider N. (2019) Humanized antibodies with increased stability. Patent number: US10280222B2. Assignee: Innate Pharma SA. Priority date: 12/03/2015. Publication date: 07/05/2019.
3. Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H, Rowland-Jones S, Braud VM. (2004) Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol, 34 (6): 1673-9. [PMID:15162437]
4. Kollnberger S, Chan A, Sun MY, Chen LY, Wright C, di Gleria K, McMichael A, Bowness P. (2007) Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide. Eur J Immunol, 37 (5): 1313-22. [PMID:17407096]
5. Marie-Cardine A, Viaud N, Thonnart N, Joly R, Chanteux S, Gauthier L, Bonnafous C, Rossi B, Bléry M, Paturel C et al.. (2014) IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res, 74 (21): 6060-70. [PMID:25361998]
6. Sicard H, Bonnafous C, Morel A, Bagot M, Bensussan A, Marie-Cardine A. (2015) A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. Oncoimmunology, 4 (9): e1022306. [PMID:26405593]
7. Sivori S, Falco M, Carlomagno S, Romeo E, Soldani C, Bensussan A, Viola A, Moretta L, Moretta A. (2010) A novel KIR-associated function: evidence that CpG DNA uptake and shuttling to early endosomes is mediated by KIR3DL2. Blood, 116 (10): 1637-47. DOI: 10.1182/blood-2009-12-256586 [PMID:20147700]
8. Thonnart N, Caudron A, Legaz I, Bagot M, Bensussan A, Marie-Cardine A. (2014) KIR3DL2 is a coinhibitory receptor on Sézary syndrome malignant T cells that promotes resistance to activation-induced cell death. Blood, 124 (22): 3330-2. DOI: 10.1182/blood-2014-09-598995 [PMID:25414436]
9. Van Der Weyden C, Bagot M, Neeson P, Darcy PK, Prince HM. (2018) IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs, 27 (8): 691-697. [PMID:30001170]
CD molecules: KIR3DL2 (CD158K). Last modified on 11/08/2026. Accessed on 17/11/2026. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=3067.